FILING ANALYSIS · THURSDAY, NOVEMBER 12
enGene Therapeutics Inc. ENGN — 8-K: Results of Operations and Financial Condition
neutral
The company reported preliminary financial information, including $245.8 million in cash, cash equivalents, and marketable securities as of October 31, 2026, and announced results from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial of detalimogene, with alignment with the FDA on key components of the planned Biologics License Application. However, the information is preliminary and subje
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →